课题基金 / 基金详情

Development of drug delivery systems for cytokines with an aim of efficient exertion of their pharmacological effect

Development of drug delivery systems for cytokines with an aim of efficient exertion of their pharmacological effect
开发细胞因子给药系统,以有效发挥其药理作用
批准号:
06557132
负责人:
SUGIYAMA Yuichi
金额:
$6.21万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
财政年份:
1994
资助国家:
日本
项目状态:
已结题
起止时间:
1994 至 1995

项目摘要

项目成果

SUGIYAMA Yuichi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In this year, we atte mpted to clarify the elimination mechanism of hepatocyte growth factor (HGF), which is expected to be developed as a treatment for certain types of liver diseases, and to develop its drug delivery system considering its elimination mechanism. In addition, we also investigated the clearance mechanism for granulocyte-colony stimulating factor (G-CSF) analog, which is now developed as a treatment for bone suppression during cancer chemotherapy. To characterize the clearance mechanism of HGF,we examined its pharmacokinetics in rats after partial hepatectomy. Based on the findings in both in vivo and perfused liver system, we demonstrate that both receptor-mediated endocytosis and the other nonspecific uptake mechanism in the liver contribute to the over all disposition of HGF.Furthermore, in the liver-diseased conditions such as partial hepatectomy, HGF clearance via the former mechanism is dramatically downregulated while that via the latter mechanism is maintained a … More t the normal level (K.Liu et al.Am.j.Physiol., 269 : G1-G9,1995). The latter clearance mechanism, which is presumably the uptake of HGF by cell-surface heparin-like substance, is found out not only a the liver parenchymal cells (hepatocytes), but also at the non-parenchymal cells. The nonspecific uptake at the non-parenchymal cells contributs to the HGF disposition especially at the higher dose, which results in the pharmacological action of HGF (Ke-Xin Liu et al.Pharm.Res.12 : 1737-1740,1995). To suppress such a nonspecific elimination, HGF was incubated with heparin to form heparin-HGF complex, and subsequently administered into the ANIT-treated rats. Several marker enzyme levels for the livery injury (such as GOT,GPT,ALP,and LAP) were dramatically decreased after the administration of such heparin-HGF complex, compared with those values after the administration of HGF alone. Plasma clearance of HGF after the injection of complex was much lower than that after the injection of HGF alone, suggesting that this heparin-HGF complex can be a candidate for the drug delivery system for HGF (In preparation for submission to journal). However, stimulation of DNA synthesis in the liver, assessed by the labeling index technique, was comparable between for the heparin-HGF complex and HGF alone, implying that further studies are required for the adequate drug delivery system for HGF.Based on the pharmacokinetic analysis of the G-CSF analog, we found out that not the liver nor the kidney, but the bone marrow is the major clearance organ for G-CSF analog (T.Kuwabara et al.Am.J.Physiol., 269 : E1-E9,1995 ; T.Kuwabara et al.J.Pharmacol.Exp.Ther., 273 : 1114-1122,1995). Less
期刊论文(32)
专著(0)
科研奖励(0)
会议论文
T. Kuwabara: "Non-linear pharmacokinetics of the recombinant Granulocyte colony-stimulating factor Nartograstim: Species differences among rats, monkeys and humans." J. Pharmacol. Exp. Therap.271. 1535-1543 (1994)
T. Kuwabara:“重组粒细胞集落刺激因子那托司亭的非线性药代动力学:大鼠、猴子和人类之间的物种差异。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T. Kuwabara: "Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats." Pharm. Res.12. 1466-1469 (1995)
T. Kuwabara:“重组粒细胞集落刺激因子那托司亭在大鼠中的肾清除率。”
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Kuwabara, T.Uchimura, H.Kobayashi, S.Kobayashi and Y.Sugiyama: "Receptor-mediated clearance of G-CSF deribvative nartograstim in bone marrow of rats." Am.J.Physiol.269 (Endocrino.Metab.32). E1-E9 (1995)
T.Kuwabara、T.Uchimura、H.Kobayashi、S.Kobayashi 和 Y.Sugiyama:“大鼠骨髓中 G-CSF 衍生物那托司亭的受体介导清除”。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
T.Kuwabara, T.Uchimura, K.Takai, H.Kobayashi, S.Kobayashi and Y.Sugiyama: "Saturable uptake of a recombinant human granulocyte colony-stimulating factor derivative, nartograstim, by the bone marrow and spleen of rats in vivo." J.Pharmacol.Exp.Ther.273. 11
T.Kuwabara、T.Uchimura、K.Takai、H.Kobayashi、S.Kobayashi 和 Y.Sugiyama:“体内大鼠骨髓和脾脏对重组人粒细胞集落刺激因子衍生物那托司亭的饱和摄取
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
30
    Development of probe drugs for the evaluation of the functions of drug transporters in vivo in humans
    • 批准号:
      20249008
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $29.7万
    • 财政年份:
      2008
    • 负责人:
      SUGIYAMA Yuichi
    • 依托单位:
    Development of the quantitative prediction method of pharmacokinetics with considering the function of metabolic enzymes and transporters
    • 批准号:
      17209005
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $31.78万
    • 财政年份:
      2005
    • 负责人:
      SUGIYAMA Yuichi
    • 依托单位:
    New strategy for the drug development of CNS acting drugs by regulating drug transport across the blood-brain barrier
    • 批准号:
      15390035
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $7.94万
    • 财政年份:
      2003
    • 负责人:
      SUGIYAMA Yuichi
    • 依托单位:
    Development of the system for prediction of drug-drug interactions in hepatobiliary transport process
    • 批准号:
      13557219
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.45万
    • 财政年份:
      2001
    • 负责人:
      SUGIYAMA Yuichi
    • 依托单位:
    海外基金